HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Insulin glulisine. Aventis Pharma.

Abstract
Aventis Pharma (formerly Hoechst Marion Roussel) is developing insulin glulisine, a fast-acting insulin analog, for the potential treatment of hyperglycemia in both type 1 and 2 diabetes. Aventis has submitted an NDA and an MAA to the FDA and the EMEA, respectively.
AuthorsDaniela Barlocco
JournalCurrent opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 4 Issue 10 Pg. 1240-4 (Oct 2003) ISSN: 1472-4472 [Print] England
PMID14649217 (Publication Type: Journal Article, Review)
Chemical References
  • Hypoglycemic Agents
  • Insulin
  • insulin glulisine
Topics
  • Animals
  • Clinical Trials, Phase II as Topic
  • Clinical Trials, Phase III as Topic
  • Diabetes Mellitus, Type 1 (drug therapy)
  • Diabetes Mellitus, Type 2 (drug therapy)
  • Humans
  • Hypoglycemic Agents (adverse effects, chemical synthesis, pharmacokinetics, therapeutic use)
  • Insulin (adverse effects, analogs & derivatives, chemical synthesis, pharmacokinetics, therapeutic use)
  • Structure-Activity Relationship

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: